MADRIGAL PHARMACEUTICALS, INC. Contracts & Agreements
108 Contracts & Agreements
- Business Finance (55 contracts)
- Business Operations (13)
- Human Resources (15)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (6)
- Uncategorized (16)
- Underwriting Agreement, dated March 18, 2024 (Filed With SEC on March 20, 2024)
- Form of Indemnification Agreement between the Registrant and certain directors and executive officers (Filed With SEC on February 28, 2024)
- Underwriting Agreement, dated September 28, 2023 (Filed With SEC on October 2, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on October 2, 2023)
- Letter Agreement (including agreements attached as exhibits thereto), dated as of September 7, 2023, by and between Madrigal Pharmaceuticals, Inc. and William Sibold (Filed With SEC on September 13, 2023)
- Registration Rights Agreement, dated August 7, 2023, by and among Madrigal Pharmaceuticals, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P (Filed With SEC on August 8, 2023)
- Form of RSU Agreement for Directors (Filed With SEC on August 8, 2023)
- Form of RSU Agreement for Executive Officers (Filed With SEC on August 8, 2023)
- Form of RSU Agreement for Employees (Filed With SEC on August 8, 2023)
- Amendment No. 1 to Sales Agreement, dated May 9, 2023, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC (Filed With SEC on May 9, 2023)
- Description of Securities of the Registrant (Filed With SEC on February 23, 2023)
- Form of Restricted Stock Unit Agreement under Amended 2015 Stock Plan (Filed With SEC on February 23, 2023)
- Form of Tranche 2 Warrant Agreement, dated February 3, 2023, by and among Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates (Filed With SEC on February 9, 2023)
- Loan and Security Agreement, dated May 9, 2022, as amended by the First Amendment to Loan and Security Agreement, dated February 3, 2023, by and among Madrigal Pharmaceuticals,... (Filed With SEC on February 9, 2023)
- Securities Purchase Agreement, dated December 21, 2022, by and among Madrigal Pharmaceuticals, Inc. and the institutional investors listed on the signature pages thereto (Filed With SEC on December 23, 2022)
- Amendment No. 2, dated December 22, 2022, to Securities Purchase Agreement, dated June 20, 2017, by and among Madrigal Pharmaceuticals, Inc. and the investors listed on the... (Filed With SEC on December 23, 2022)
- Form of Warrant Agreement, dated May 9, 2022, between Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates (Filed With SEC on August 4, 2022)
- Loan and Security Agreement, dated May 9, 2022, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or... (Filed With SEC on August 4, 2022)
- Sales Agreement, dated June 1, 2021, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC (Filed With SEC on June 1, 2021)
- Non-Employee Director Equity Compensation Policy (Filed With SEC on May 6, 2021)
- Sales Agreement, dated November 5, 2020, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC (Filed With SEC on November 5, 2020)
- Form of Nonqualified Stock Option Agreement for Directors under Amended 2015 Stock Plan (Filed With SEC on August 6, 2020)
- Description of Securities of the Registrant (Filed With SEC on February 26, 2020)
- Underwriting Agreement, dated December 10, 2019, by and among Madrigal Pharmaceuticals, Inc., the Selling Stockholders, and Goldman Sachs & Co. LLC (Filed With SEC on December 12, 2019)
- Office lease entered into as of January 10, 2019 with Four Tower Bridge Associates, a Pennsylvania Limited Partnership (Filed With SEC on May 8, 2019)
- Underwriting Agreement, dated June 6, 2018, by and between Madrigal Pharmaceuticals, Inc, Goldman Sachs & Co. LLC as Representative of the Underwriters set forth therein, and the... (Filed With SEC on June 8, 2018)
- Underwriting Agreement, dated December 18, 2017, by and between Madrigal Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC as Representative of the Underwriters set forth therein (Filed With SEC on December 21, 2017)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 21, 2017)
- RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on November 14, 2016)
- MADRIGAL PHARMACEUTICALS, INC. AMENDED 2015 STOCK PLAN (Filed With SEC on July 22, 2016)
- INDEMNIFICATION AGREEMENT (Filed With SEC on July 22, 2016)
- [Madrigal Letterhead] (Filed With SEC on July 22, 2016)
- [Madrigal Letterhead] (Filed With SEC on July 22, 2016)
- SYNTA PHARMACEUTICALS CORP. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Companys 2015 Stock Plan (Filed With SEC on May 10, 2016)
- LEASE TERMINATION AGREEMENT (Filed With SEC on April 22, 2016)
- AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SYNTA PHARMACEUTICALS CORP., a Delaware corporation; SAFFRON MERGER SUB, INC. a Delaware corporation; and MADRIGAL... (Filed With SEC on April 14, 2016)
- VOTING AGREEMENT among: SYNTA PHARMACEUTICALS CORP., a Delaware corporation; MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation; and the undersigned Stockholder Dated as of... (Filed With SEC on April 14, 2016)
- VOTING AGREEMENT among: MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation; SYNTA PHARMACEUTICALS CORP., a Delaware corporation; and the undersigned Stockholder Dated as of... (Filed With SEC on April 14, 2016)
- LOCK-UP AGREEMENT (Filed With SEC on April 14, 2016)
- ELEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on November 5, 2015)
- SYNTA PHARMACEUTICALS CORP. $100,000,000 SALES AGREEMENT (Filed With SEC on October 16, 2015)
- SYNTA PHARMACEUTICALS CORP. AMENDED AND RESTATED* DIRECTOR COMPENSATION POLICY (Filed With SEC on August 6, 2015)
- UPDATED OFFER LETTER (Filed With SEC on August 6, 2015)
- SYNTA PHARMACEUTICALS CORP. 2015 STOCK PLAN (Filed With SEC on June 15, 2015)
- Employee Retention and Incentive Bonus Plan As adopted by the Compensation Committee on March 2, 2015 (Filed With SEC on May 7, 2015)
- 22,000,000 Shares Synta Pharmaceuticals Corp. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 1, 2015)
- SYNTA PHARMACEUTICALS CORP. December 8, 2014 (Filed With SEC on March 12, 2015)
- SYNTA PHARMACEUTICALS CORP. December 8, 2014 (Filed With SEC on March 12, 2015)
- RESTRICTED STOCK AGREEMENT SYNTA PHARMACEUTICALS CORP. (Filed With SEC on March 12, 2015)
- RESTRICTED STOCK AGREEMENT SYNTA PHARMACEUTICALS CORP. (Filed With SEC on March 12, 2015)
- SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on December 4, 2014)
- SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on December 4, 2014)
- RESTRICTED STOCK AGREEMENT SYNTA PHARMACEUTICALS CORP. (Filed With SEC on November 6, 2014)
- SYNTA PHARMACEUTICALS CORP. September 2, 2014 (Filed With SEC on November 6, 2014)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 6, 2014)
- SYNTA PHARMACEUTICALS CORP. Common Stock (par value $0.0001 per share) At the Market Issuance Sales Agreement (Filed With SEC on July 18, 2014)
- TENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on July 18, 2014)
- SYNTA PHARMACEUTICALS CORP. AMENDED AND RESTATED* DIRECTOR COMPENSATION POLICY (Filed With SEC on May 8, 2014)
- SYNTA PHARMACEUTICALS CORP. Common Stock (par value $0.0001 per share) At the Market Issuance Sales Agreement (Filed With SEC on May 8, 2014)
- SUBSCRIPTION AGREEMENT (Filed With SEC on April 14, 2014)
- Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 March 19, 2014 (Filed With SEC on March 20, 2014)
- NINTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on December 2, 2013)
- 14,000,000 Shares Synta Pharmaceuticals Corp. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 14, 2013)
- SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on April 30, 2013)
- EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 1, 2013)
- AMENDED AND RESTATED PROMISSORY NOTE March 28, 2013 $12,500,000 (Filed With SEC on April 1, 2013)
- AMENDED AND RESTATED PROMISSORY NOTE March 28, 2013 $10,000,000 (Filed With SEC on April 1, 2013)
- SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on March 14, 2013)
- SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on December 20, 2012)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on December 13, 2012)
- First Amendment to At the Market Issuance Sales Agreement (Filed With SEC on December 13, 2012)
- FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 2, 2012)
- SUBSCRIPTION AGREEMENT (Filed With SEC on July 26, 2012)
- SYNTA PHARMACEUTICALS CORP. Common Stock (par value $0.0001 per share) At the Market Issuance Sales Agreement (Filed With SEC on May 3, 2012)
- SYNTA PHARMACEUTICALS CORP. AMENDED AND RESTATED* DIRECTOR COMPENSATION POLICY (Filed With SEC on May 3, 2012)
- FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 22, 2012)
- 7,000,000 Shares Synta Pharmaceuticals Corp. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 6, 2012)
- SYNTA PHARMACEUTICALS CORP. THIRD AMENDMENT TO THE AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on December 1, 2011)
- AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 19, 2011)
- EXHIBIT 1 BASIC PROVISIONS AND LEASE REFERENCE DATA (Filed With SEC on August 4, 2011)
- FIRST AMENDMENT TO LEASE (Filed With SEC on August 4, 2011)
- THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 4, 2011)
- THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on July 21, 2011)
- SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 5, 2011)
- SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on May 5, 2011)
- THIRD AMENDMENT TO COMMERCIAL LEASE (Filed With SEC on April 22, 2011)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on April 15, 2011)
- FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on March 11, 2011)
- SUBSCRIPTION AGREEMENT (Filed With SEC on November 12, 2010)
- LOAN AND SECURITY AGREEMENT (Filed With SEC on October 5, 2010)
- PROMISSORY NOTE (Filed With SEC on October 5, 2010)
- PROMISSORY NOTE (Filed With SEC on October 5, 2010)
- GUARANTY (Filed With SEC on October 5, 2010)
- PLEDGE AGREEMENT (Filed With SEC on October 5, 2010)
- COMMON STOCK PURCHASE AGREEMENT Dated as of October 4, 2010 by and between SYNTA PHARMACEUTICALS CORP. and AZIMUTH OPPORTUNITY LTD. (Filed With SEC on October 5, 2010)
- AMENDMENT TOCOLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 4, 2010)
- FORM OF SEVERANCE AND CHANGE OF CONTROL AGREEMENT WITHSENIOR VICE PRESIDENTS (Filed With SEC on March 11, 2010)
- FORM OF SEVERANCE AND CHANGE OF CONTROL AGREEMENT WITH VICE PRESIDENTS (Filed With SEC on March 11, 2010)
- 5,555,556 Shares of CommonStock par value $0.0001 SYNTA PHARMACEUTICALS CORP. UNDERWRITING AGREEMENT (Filed With SEC on January 8, 2010)
- 125 Hartwell Avenue Lexington, Massachusetts02421 (the Building) NINTH AMENDMENT May 19, 2009 (Filed With SEC on August 4, 2009)
- SYNTA PHARMACEUTICALS CORP. AMENDED AND RESTATED* DIRECTOR COMPENSATION POLICY (Filed With SEC on August 4, 2009)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 26, 2009)
- SECOND AMENDMENT TO COMMERCIAL LEASE (Filed With SEC on August 7, 2008)
- 125 Hartwell Avenue Lexington, Massachusetts 02421 (the Building) EIGHTH AMENDMENT June 19,2008 (Filed With SEC on August 7, 2008)
- SYNTA PHARMACEUTICALS CORP. AMENDED AND RESTATED* DIRECTOR COMPENSATION POLICY (Filed With SEC on August 7, 2008)
- Amendment No. 1 toCollaborative Development, Commercialization and License Agreement (Filed With SEC on August 7, 2008)
- SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on April 29, 2008)
- SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on April 29, 2008)